Answers are grounded in this paper and cite their sources.
Hyperuricemia is a metabolic disorder characterized by elevated serum uric acid levels resulting from an imbalance between uric acid production and excretion. Persistent hyperuricemia contributes to gout, chronic kidney disease, cardiovascular disorders, oxidative stress, and systemic inflammation. Conventional xanthine oxidase inhibitors, such as allopurinol and febuxostat, are effective but prompt research into natural compounds as alternative therapeutic agents. Natural products contain numerous bioactive compounds with antioxidant, anti-inflammatory, and xanthine oxidase-inhibiting activities, which have attracted significant attention for further study. This narrative review aims to summarize the latest evidence regarding the molecular mechanisms of several bioactive compounds in combating hyperuricemia based on a network pharmacology approach. Literature was collected from PubMed, ScienceDirect, Google Scholar, and Semantic Scholar using the keywords “natural product,” “hyperuricemia,” and “network pharmacology.” A total of 11 studies meeting the inclusion criteria were identified, published between 2022 and 2025. The findings consistently showed that network pharmacology successfully identified various therapeutic targets associated with hyperuricemia, including TNF, IL-6, CASP3, AKT1, PPARG, ESR1, TP53, VEGFA, PTGS2, and STAT3. Enrichment analysis revealed that the PI3K/Akt, TNF, MAPK, IL-17, NF-?B, HIF-1, AGE-RAGE, and NOD-like receptor signaling pathways are the primary biological pathways involved. Overall, network pharmacology provides comprehensive insights into the molecular basis of target proteins in the treatment of hyperuricemia and offers promising strategies for future drug discovery.
No takes yet. Share an insight, caveat, or question.
Indawati et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: